Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Finance
    3. >Ro CEO says Wegovy pill is bringing in new customers, including men
    Finance

    Ro CEO Says Wegovy Pill Is Bringing in New Customers, Including Men

    Published by Global Banking & Finance Review®

    Posted on January 28, 2026

    3 min read

    Last updated: January 28, 2026

    Add as preferred source on Google
    Ro CEO says Wegovy pill is bringing in new customers, including men - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:customersinsurancehealthcareAdvertising

    Quick Summary

    Ro's new Wegovy pill is attracting new customers, including men, due to its convenience and competitive pricing. The company plans major advertising campaigns to boost awareness.

    Ro CEO says Wegovy pill is bringing in new customers, including men

    Wegovy Pill's Impact on Customer Demographics

    By Amina Niasse

    Convenience and Pricing

    NEW YORK, Jan 28 (Reuters) - Telehealth company Ro has had an influx of new customers seeking the newly launched pill version of Wegovy to lose weight, including men who have shied away from taking the popular injection form, Ro CEO Zach Reitano said.

    Advertising Strategies

    The increased demand is due to the convenience of a pill versus an injection and its lower introductory price of $149 per month.

    Addressing Stigma Around GLP-1 Drugs

    Patients who pay a monthly member fee can purchase the drug for between $149 for the lowest dose and $299 for the highest dose. That $149 is good through mid-April. Novo offers the same pricing on its website. Patients who have insurance coverage may pay less.

    Telehealth firms like privately held Ro have grown quickly as demand for GLP-1 drugs has surged, with shortages, high prices and insurance hurdles pushing patients toward direct-to-consumer platforms. New York-based Ro sells Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy through partnerships.

    Wegovy, like Ozempic, the drug developed for type 2 diabetes, is based on the active ingredient semaglutide. The drug mimics a gut hormone that suppresses appetite and makes people feel full for longer.

    Launched on January 5, Wegovy is the only GLP-1 pill approved for weight loss on the market. The FDA is currently reviewing Lilly's competing pill and is expected to approve it in April.

    Ro said it is planning a major advertising promotion for the Super Bowl, a commercial featuring tennis star Serena Williams, and the launch of the company's “Healthier on Ro” campaign, which highlights benefits beyond weight loss, including joint pain relief.

    Williams in media interviews has challenged what she described as the stigma around using the GLP-1 drugs, namely that patients on the treatments are lazy.

    "We hope that these ads continue to fight against the stigma associated with GLP-1s and educate people about their options," a spokesperson for the company said.

    The Super Bowl, the National Football League’s annual championship, is routinely the most-watched television event in the United States and a centerpiece for advertising.

    According to ratings firm Nielsen, over 100 million people watch the event each year. An Adweek report said a 30-second slot costs around $8 million.

    (Reporting by Amina Niasse; Editing by Caroline Humer and Lisa Shumaker)

    Table of Contents

    • Wegovy Pill's Impact on Customer Demographics
    • Convenience and Pricing
    • Advertising Strategies
    • Addressing Stigma Around GLP-1 Drugs

    Key Takeaways

    • •Ro's Wegovy pill attracts new customers, including men.
    • •The pill offers convenience over injections.
    • •Pricing starts at $149, appealing to new users.
    • •Ro plans major advertising, including a Super Bowl ad.
    • •Wegovy is the only FDA-approved GLP-1 pill for weight loss.

    Frequently Asked Questions about Ro CEO says Wegovy pill is bringing in new customers, including men

    1What is Wegovy?

    Wegovy is a prescription medication approved for weight loss that comes in a pill form. It contains the active ingredient semaglutide, which mimics a gut hormone to suppress appetite.

    2What is the role of insurance in medication costs?

    Insurance can significantly lower the out-of-pocket costs for medications by covering part of the expenses, depending on the patient's policy and the medication prescribed.

    More from Finance

    Explore more articles in the Finance category

    Image for Israel strikes Tehran as Trump says US negotiating to end war
    Israel Strikes Tehran as Trump Says US Negotiating to End War
    Image for South Korea, Germany exposed to rare earths shortage, Australia's Arafura says
    South Korea, Germany Exposed to Rare Earths Shortage, Australia's Arafura Says
    Image for Currency markets drift as traders sceptical of US efforts to end Iran war
    Currency Markets Drift as Traders Sceptical of US Efforts to End Iran War
    Image for Stocks bounce and oil retreats on Mideast ceasefire reports
    Stocks Bounce and Oil Retreats on Mideast Ceasefire Reports
    Image for Equinor CEO says EU unlikely to increase Russian gas imports
    Equinor CEO Says EU Unlikely to Increase Russian Gas Imports
    Image for Openreach taps Google AI to speed fibre rollout, cut emissions
    Openreach Taps Google AI to Speed Fibre Rollout, Cut Emissions
    Image for UK consumer sentiment falls as Iran war rages, KPMG says
    UK Consumer Sentiment Falls as Iran War Rages, Kpmg Says
    Image for US oil prices fall on prospect of Middle East ceasefire easing supply disruption
    US Oil Prices Fall on Prospect of Middle East Ceasefire Easing Supply Disruption
    Image for Lamborghinis stranded in Sri Lanka as war disrupts Asia's used-car trade 
    Lamborghinis Stranded in Sri Lanka as War Disrupts Asia's Used-Car Trade 
    Image for Britain pilots social media bans, time limits and curfews for children
    Britain Pilots Social Media Bans, Time Limits and Curfews for Children
    Image for UK's Starmer, Saudi crown prince discussed ongoing Middle East conflict, Downing Street says
    UK's Starmer, Saudi Crown Prince Discussed Ongoing Middle East Conflict, Downing Street Says
    Image for Grifols approves IPO of its US biopharma business
    Grifols Approves IPO of Its US Biopharma Business
    View All Finance Posts
    Previous Finance PostTether CEO Aims to Allocate up to 15% of Its Portfolio to Gold
    Next Finance PostVolkswagen Looks to Asia, Middle East for Export Opportunities From China